



October 8, 2020

PRESS RELEASE

Company: RaQualia Pharma Inc.

(Ticker code: 4579)

Representative: Representative Director Naoki Tani

Inquiries: Director Kiichiro Kawada

(Phone +81-52-446-6100)

**Elanco Japan Launched Galliprant Tablets (Selective EP4 Antagonist/Anti-inflammatory Analgesic for Canine Chronic Osteoarthritis) in Japan**

RaQualia Pharma Inc. (RaQualia) is pleased to announce that Elanco Japan K.K. headquartered in Minato-ku, Tokyo (President & Representative Director, Philip Huggenberger), the Japanese subsidiary of Elanco Animal Health Inc. (Headquarter: Indiana, the U.S.A., hereinafter called “Elanco”), launched Galliprant tablets (generic name: Grapiprant, hereinafter called “Galliprant”) as a selective EP4 antagonist/an anti-inflammatory analgesic for the treatment of canine chronic osteoarthritis in Japan.

Galliprant is a first-in-class piroxicam anti-inflammatory analgesic that selectively antagonizes the EP4 receptor, one of prostaglandin receptors. It has a unique new mechanism of action, targeting pain and inflammation while reducing the alteration on gastrointestinal tracts, kidneys and liver. The safety profile of Galliprant has been confirmed in a repeated dosing 9-month long-term safety study. Galliprant tablets will be available in two dosage forms in Japan: 20mg and 60mg. Since its launch in the U.S.A. in January 2017, Galliprant has been marketed in more than 20 countries and the sales are steadily increasing.

“We are very pleased to offer Galliprant as a new treatment option to Japanese pet owners. RaQualia will continue to work with Elanco to meet the expectations of veterinarians and pet owners. We remain dedicated to developing drug discovery business so that we can provide innovative therapies around the world,” said Mr. Naoki Tani, President and CEO of RaQualia.

In December 2010, RaQualia entered into a licensing agreement with Aratana Therapeutics Inc. (currently Elanco) regarding the worldwide commercialization of its EP4 antagonist as veterinary drugs. RaQualia is eligible to receive a fixed rate of royalty on the sales of the product.

Galliprant is one of RaQualia’s core products. We expect that the expansion of Galliprant sales will contribute to increasing our brand recognition and corporate value in Japan. RaQualia will support Elanco’s marketing activities to accelerate the sales of Galliprant around the world.

RaQualia will not receive milestones in connection with this matter. The financial forecasts for the fiscal year 2020 (Jan. 1, 2020 – Dec. 31, 2020) issued on August 14, 2020 will not be affected by this announcement.

References:

Galliprant tablets packages in Japan



Galliprant Tablets 20mg



Galliprant Tablets 60mg